SOURCE: CBLPath

CBLPath

November 17, 2010 09:15 ET

CBLPath Announces Validation of Additional FISH Testing

New Molecular Tests Increase Ability to Provide Comprehensive Diagnostic, Prognostic Information

RYE BROOK, NY--(Marketwire - November 17, 2010) - CBLPath has received approval from the New York State Department of Health to offer several new molecular tests as part of its comprehensive menu. The recently approved tests -- BCR/ABL, CLL, MDS, Multiple Myeloma Panels -- facilitate diagnostic and prognostic testing for diseases of the blood and bone marrow.

Fluorescence in situ hybridization (FISH) provides researchers with a way to visualize and map the genetic material in an individual's cells, including specific genes or portions of genes. This is important for understanding a variety of chromosomal abnormalities and other genetic mutations. Unlike most other techniques used to study chromosomes, FISH does not have to be performed on cells that are actively dividing. This makes it a very versatile procedure.

"The addition of these molecular tests will provide our clients and patients with expert clinical care consistent with our pursuit of the best and most advanced laboratory practices available," said Dr. Carlos D. Urmacher, CBLPath's Chief Medical Officer. "The accessibility of these tests by our medical professionals will augment our existing laboratory menu and will serve to enhance the proficiency, accuracy and versatility of our diagnostic and prognostic methodology."

These tests are additive to CBLPath's current menu encompassing more than 440 IHC stains, Flow cytometry, FISH and Molecular Diagnostics. Working with CBLPath, clients have access to molecular, anatomic and digital pathology services. By simultaneously offering these methodologies, CBLPath is enabling clients to take advantage of the industry convergence; bringing together the best of all methodologies and technologies to enable to most accurate diagnosis and patient care.

"Since the company's inception, CBLPath has prided itself on providing high quality results to our clients, enabling delivery of superlative care to their patients," said David W. Bryant, CBLPath's Chairman of the Board and President. "The results from these tests will enable our clients to make better decisions about their patients' disease; providing direction for the most efficacious therapies."

CBLPath will showcase its molecular test offering as well as the Best Practice™ Partnership Program -- used by pathologists to embrace the value of the industry convergence, keeping medicine local -- at the AMP 2010 meeting being held this week in San Jose. For more information, please visit www.CBLPath.com.

About CBLPath
CBLPath is a national specialty lab offering a full convergence of anatomic, molecular and digital pathology services. The company provides a one-stop solution for comprehensive sub-specialized diagnostics, and timely, accurate, patient-centered disease management guidance. Through its Best Practice™ Partnership Program, CBLPath partners with pathologists to help them grow their practices, while giving them the ability to stay independent and "keep medicine local." The company also provides sub-specialty physicians access to comprehensive, high-quality testing in their local market. Founded in 1988, CBLPath established a reputation for providing timely, highly accurate diagnoses along with extraordinary customer service and a true patient-centered commitment. For more about the company, please visit www.CBLPath.com.